Premium
Dietary Flaxseed Is Protective Against Lung Cancer Cell Proliferation And Tumor Growth In The Flanks Of Mice
Author(s) -
Lee James C,
Arguiri Evguenia,
Cheng Guanjun,
Solomides C. C.,
ChristofidouSolomidou Melpo
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.5.a58
Subject(s) - lung cancer , cancer , cell growth , medicine , in vivo , cancer research , cell culture , cancer cell , endocrinology , chemistry , biology , biochemistry , genetics , microbiology and biotechnology
Flaxseed (FS), a nutritional supplement, has high contents of omega‐3 fatty acids and lignans with known anti‐carcinogenic properties. Its use in lung cancer therapy has never been evaluated. In this study we evaluated tumor growth of lung cancer cell lines in mice fed FS‐supplemented diets. Mice were fed 10% FS or 0% FS control diets for 2–3 weeks and injected in the flank with one million cells of the following murine cancer cell lines: TC‐1 (lung cancer); LLC (Lewis lung carcinoma); AB12 (mesothelioma); and LKR (a lung cancer cell line derived from Kras‐tumors). Tumor volume and growth rate were measured using calipers over a period of several weeks. In addition, cell proliferation of the same cell lines was evaluated in vitro in the presence of physiologic concentrations of the FS lignans enterolactone (EL) and enterodiole (ED). At the time of sacrifice (9–18 days post flank injection), tumor burden in the flanks of 10% FS‐fed mice compared to 0% FS‐fed mice was reduced by 13–36% depending on the cell line (n=5 each group, p<0.05). Also, the FS lignans EL and ED inhibited up to 30–60% of the proliferation of the same cancer cell lines in vitro. Dietary FS and its lignans are protective against lung cancer cell proliferation in vitro and tumor growth in vivo and may be useful as adjuvant therapeutic agents in the treatment of lung cancer patients. Funded by: NIHR21, AICR and U. Penn Research Foundation (MCS).